• DurAVR THV demonstrated a favorable hemodynamic profile sustained to one-year
• No valve or cardiovascular related mortality and no prosthesis-patient mismatch reported
• One-year data will be included in the planned Investigational Device Exemption (IDE) submission to the U.S. FDA

Anteris Technologies Global Corp. (Nasdaq: AVR, ASX: AVR) announced one-year results for patients treated with its proprietary, balloon expandable, DurAVR Transcatheter Heart Valve (THV) System. The data will be presented by Rishi Puri, M.D. PhD at a late breaking clinical trial session at Sydney Valves on Friday, 21 March 2025. The one-year results showed that the DurAVR THV demonstrated a favorable hemodynamic profile sustained to one-year, with an Effective Orifice Area (EOA) of 2.1 + 0.2 cm2, a Mean Pressure Gradient (MPG) of 8.6 + 2.6 mmHg and Doppler Velocity Index (DVI) of 0.58. Importantly, at one-year, there was no valve or cardiovascular related mortality and no prosthesis-patient mismatch (PPM) reported in these small annuli patients (aortic annulus area 395.80 + 37.26mm2). The one-year data builds on the existing body of clinical evidence and will be included in the planned Investigational Device Exemption (IDE) submission to the U.S. FDA to seek approval to conduct the DurAVR THV randomized, global pivotal study.